Sort
21,453 grants matching “tuberculosis”
URBAN ARCH (3/5) Uganda Cohort TB preventive therapy for HIV-infected alcohol users in Uganda: an evaluation of safety tolerability and adherence
$588,006Judith Alissa Hahn · University Of California, San Francisco · U01 · FY2020 · AA
Mechanisms of increased susceptibility to pulmonary Nontuberculous Mycobacterial disease in the elderly
$588,003Ilhem Messaoudi · University Of California-Irvine · R01 · FY2020 · AI
Innovative contact tracing strategies for detecting TB in mobile rural and urban South African populations
$587,975David Wesley Dowdy · Johns Hopkins University · R01 · FY2020 · AI
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity
$587,913Jonathan E Golub · Johns Hopkins University · R01 · FY2024 · AI
Vaccine and Treatment Evaluation Unit at Saint Louis University
$587,832Daniel F. Hoft · Saint Louis University · UM1 · FY2022 · AI
Genetics of TB resistance in HIV positive subjects
$587,669Catherine Marie Stein · Case Western Reserve University · R56 · FY2017 · AI
Methods for Evaluating Vaccine Efficacy
$587,667M Elizabeth Halloran · Fred Hutchinson Cancer Research Center · R37 · FY2017 · AI
Regulation of Immune Responses to Mycobacterium tuberculosis Infection
$587,643Christina Leigh Stallings · Washington University · R01 · FY2018 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence
$587,529Veronique Dartois · Boston Medical Center · U19 · FY2017 · AI
Durability of systemic and lung immune correlates of BCG-induced protection against M. tuberculosis infection
$587,434Elisa Nemes · University Of Cape Town · R01 · FY2025 · AI
Smart stethoscope for monitoring and diagnosis of lung diseases
$587,391Mounya Elhilali · Johns Hopkins University · R01 · FY2016 · HL
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
$587,361Ann R Falsey · University Of Rochester · UM1 · FY2022 · AI
Administrative Core
$587,236Janet S Butel · Baylor College Of Medicine · P30 · FY2008 · AI
How does HIV lead to increased susceptibility to tuberculosis?
$586,997David G Russell · Cornell University · R01 · FY2015 · AI
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
$586,616Awewura Jacob Kwara · University Of Florida · R01 · FY2016 · HD
Oxygen Activation and Radical Transfer in Ribonucleotide Reductase from Pathogens
$586,604Joseph M Bollinger · Pennsylvania State University, The · R01 · FY2011 · GM
Chemical Biological Discovery of Lipid Virulence Factors in the Major Bacterial Pathogens
$586,376David Branch Moody · Brigham And Women'S Hospital · R01 · FY2024 · AI
Reversing Isoniazid Resistance By Isotopic Substitution
$586,360Graham S Timmins · Spinceutica, Inc. · R44 · FY2017 · AI
Phagosomal Ion Channels as Therapeutic Targets
$586,358Deborah J. Nelson · University Of Chicago · R01 · FY2018 · HL
Innovative contact tracing strategies for detecting TB in mobile rural and urban South African populations
$586,119David Wesley Dowdy · Johns Hopkins University · R01 · FY2022 · AI
A Community Mycobacterial Systems Resource
$586,056Keith M Derbyshire · Wadsworth Center · R01 · FY2013 · AI
Linkage & Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa
$586,018Ingrid Valerie Bassett · Massachusetts General Hospital · R01 · FY2010 · MH
Persister cells of Borrelia burgdorferi
$586,005Kim Lewis · Northeastern University · R01 · FY2016 · AI
Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes
$585,914Krishna P Reddy · Massachusetts General Hospital · R01 · FY2024 · DA
Host Response to TB and AIDS
$585,882William N Rom · New York University School Of Medicine · R01 · FY2006 · HL